Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Strosberg Discusses Trials in Neuroendocrine Tumors

May 16th 2017

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).

Immunotherapy on the Cusp in HCC

May 12th 2017

Tim F. Greten, MD, discussed the evolving role of immunotherapy in hepatocellular carcinoma.

Dr. Venook Discusses the Role of Chemotherapy in Metastatic CRC

May 11th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Dr. Klompenhouwer on the Resection of Larger Hepatocellular Adenomas

May 11th 2017

Anne Julia Klompenhouwer, MD, Department of Surgery at Erasmus Medical Center in Rotterdam, The Netherlands, discusses when it is justified to resect a larger hepatocellular adenoma for patients with hepatocellular carcinoma (HCC).

Expert Discusses Progress in Neuroendocrine Tumors

May 10th 2017

Jonathan Strosberg, MD, discusses recent developments and emerging agents in the field of neuroendocrine tumors.

Dr. Meinhardt on the Impact of the RESORCE Study in HCC

May 9th 2017

Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.

Researchers Perform First Robotic Colonoscopy

May 9th 2017

Researchers have successfully performed autonomous retroflexion of a robotic capsule during colonoscopy in a subject animal, according to data presented during Digestive Disease Week 2017 at McCormick Place in Chicago.

Dr. Philip on the Importance of Developing New Drugs for Pancreatic Cancer

May 8th 2017

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

Dr. Abou-Alfa on the Role of Immunotherapy in HCC

May 6th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

Dr. Strosberg on Challenges in the Treatment of Neuroendocrine Tumors

May 4th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Dr. Yurgelun Discusses Germline Testing in CRC

May 3rd 2017

Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.

Lead CheckMate-040 Investigator Discusses Nivolumab in HCC

May 2nd 2017

Bruno Sangro, MD, PhD, discusses the CheckMate-040 data and the future of immuno-oncology agents in HCC.

Dr. Shah on the Difference in Treatment of Left- and Right-Sided Tumors in CRC

May 2nd 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.

Dr. Bruix Discusses the Application of Regorafenib in HCC

April 28th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the application of regorafenib (Stivarga) in hepatocellular carcinoma as opposed to other tumor types.

Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC

April 28th 2017

David James Pinato, MD, MRCP, PhD, faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of sorafenib (Nexavar) in pretreated patients with hepatocellular carcinoma (HCC).

Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer

April 27th 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

FDA Approves Regorafenib for Liver Cancer

April 27th 2017

The FDA has approved regorafenib (Stivarga) as a second-line treatment for patients with hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar).

Dr. Kennedy on Next Steps With SIRFLOX Trial in Liver-Metastatic CRC

April 26th 2017

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).

Expert Stresses Early Detection, Multidisciplinary Care for HCC

April 25th 2017

Amit Singal, MD, discusses the recent successes in the hepatocellular carcinoma treatment landscape and the challenges that still remain.

Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCC

April 25th 2017

Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.